ADMA
Adma Biologics Inc (ADMA)
Healthcare • NASDAQ • $8.17-3.54%
- Symbol
- ADMA
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $8.17
- Daily Change
- -3.54%
- Market Cap
- $1.89B
- Trailing P/E
- 12.01
- Forward P/E
- 7.73
- 52W High
- $22.37
- 52W Low
- $7.21
- Analyst Target
- $16.75
- Dividend Yield
- N/A
- Beta
- 0.82
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treat…
Company websiteResearch ADMA on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.